

Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April–June 2022

Irina Kislaya, Aryse Melo, Marta Barreto, Camila Henriques, Carlos Aniceto, Carla Manita, Sara Ramalhete, João Almeida Santos, Sofia Soeiro, Ana Paula Rodrigues; ISN4COVID-19 Group¹

After the rapid spread of SARS-CoV-2 BA.5 Omicron lineage in Portugal, we developed a seroepidemiologic survey based on a sample of 3,825 residents. Results indicated that from April 27 through June 8, 2022, the estimated seroprevalence of SARS-CoV-2 nucleocapsid or spike IgG was 95.8%, which indicates a high level of protection.

Serial seroepidemiologic surveys contribute information about pandemic dynamics; monitoring population-level SARS-CoV-2 antibody distribution establishes trends in postinfection and vaccine-induced immunity. Such surveys are essential to integrated surveillance systems for respiratory infections (1).

During May 2020–June 2022, the National Health Institute Doutor Ricardo Jorge, in partnership with the National Clinical Pathology Laboratories Association, the Portuguese Association of Clinical Analysts, and a nationwide network of public hospitals, conducted 4 serial seroepidemiologic surveys (ISN1COVID-19, ISN2COVID-19, ISN3COVID-19, and ISN4COVID-19). Number of study participants ranged from 2,301 to 8,463 residents of Portugal (2–4) (Figure 1). The fourth survey (ISN4COVID-19) was conducted from April 27, 2022, through June 8, 2022, after the mandatory mask mandate was lifted and during rapid spread of the SARS-CoV-2 BA.5 Omicron lineage (5) (Appendix Figure 1, <https://wwwnc.cdc.gov/EID/article/29/3/22-1546-App1.pdf>) and the ongoing second booster vaccination campaign (6) (Appendix Figure 2). We estimated SARS-CoV-2 seroprevalence, distinguishing between antibodies against the spike (S) and nucleocapsid (N)

proteins. This distinction is relevant because currently deployed vaccines elicit an immune response against the S protein, so the presence of N antibodies could be interpreted as a proxy for postinfection seroprevalence in highly vaccinated populations.

The study was approved by the Ethics Committee of the National Health Institute Doutor Ricardo Jorge. The need for participants' informed consent was waived by the Ethics Committee because of the irreversible anonymization of the data at collection sites.

The Study

Using a 2-stage nonprobability quota sampling design, we collected 3,825 irreversibly anonymized residual serum samples from persons who had undergone blood testing for reasons unrelated to COVID-19 in a nationwide network of participating clinical pathology laboratories and public hospitals (Figure 2; Appendix). For each sample, we qualitatively determined the type of IgG against SARS-CoV-2 N protein and quantitatively determined IgG against S protein by using Abbott SARS-CoV-2 Chemiluminescent Microparticle Immunoassays in the ARCHITECT i1000SR (<https://www.abbott.com>). We considered samples with S IgG levels >50 arbitrary units (AU)/mL to be positive. Total seroprevalence was defined as positivity for S or N IgG.

We stratified seroprevalence by patient sex, age group, and region of residence. To compare seroprevalence between population subgroups, we used a design-adjusted χ^2 test (7). We described the distribution of quantitative S IgG in terms of geometric means and respective 95% CIs (Appendix). We stratified estimates by patient age group, and sex. To account for

Author affiliation: Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal

DOI: <https://doi.org/10.3201/eid2903.221546>

¹Group members are listed at the end of this article.




Figure 1. Daily number of cases and percentages of SARS-CoV-2 seroprevalence in 4 serial seroepidemiologic surveys in Portugal, May 2020–June 2022. Tick marks correspond to the first day of the month.

sampling design, we weighted all estimates to match the distribution of the Portugal population by sex, age group, and region of residence. We conducted statistical analyses by using Stata 15.1 software (StataCorp LLC, <https://www.stata.com>).

From 3,825 collected residual serum samples, 27.3% were positive for N IgG, 95.0% for S IgG, and 95.8% for either N or S IgG (Table 1). Seroprevalence of N IgG was similar by sex but varied significantly by age group, highest among children (39.2% among those 0–4 years of age and 40.0% among those 10–19 years of age) and lowest (17.3%) among adults ≥ 70 years of age. The age-related pattern for seroprevalence of S IgG differed; estimated rates were lower among those 0–4 years of age (71.2%) and 5–9 years of age (78.2%) than for those in the remaining age groups. S IgG seroprevalence also was lower in Algarve (91.0%) than in other regions of Portugal. Total seroprevalence also varied by region and age group, showing patterns similar to those of S IgG.

We observed lower S IgG levels among children < 10 years of age (geometric mean 180.4 AU/mL for 0–4 and 426.6 AU/ml for 5–9 years of age). S IgG levels were also lower among persons ≥ 70 years of age (geometric mean 4,558.5 AU/mL) than among middle-aged adults. Higher S IgG levels were observed among those positive for N IgG (Table 2).

Conclusions

The fourth observational nationwide study (ISN-4COVID-19) estimated that during the early Omicron BA.5 circulation period, most residents of Portugal (95.5%, 95% CI 95.0–96.4%) had specific SARS-CoV-2 antibodies resulting from infection or vaccination. Total seroprevalence increased by ≈ 10 percentage points compared with findings from a previous survey developed during September–November 2021 (Figure 1) (4). Seropositivity in Portugal during April–June

2022 was comparable to the reported seroprevalence in Scotland during May–June 2022 (95.7%) (8) and to that in Navarra, Spain, during May–July 2022 (S IgG 92.7%) (9). Seropositivity in Portugal was also in line with the high vaccination coverage achieved in Portugal (Appendix Figure 2) (6).

Our results reveal a steep increase in N IgG seroprevalence for all age groups between the third and




Figure 2. Data collection sites for study of seroprevalence of specific SARS-CoV-2 antibodies during the Omicron BA.5 wave, Portugal, April–June 2022 (ISN4COVID-19 study). NUTSIII, territorial units for statistics level III.

Table 1. Seroprevalence of specific SARS-CoV-2 antibodies, stratified by sex, age group, and region of residence, Portugal, April 27–June 8, 2022*

Characteristic	N IgG positive, % (95% CI)	S IgG positive, % (95% CI)	N or S IgG positive, % (95% CI)
Overall	27.3 (25.5–29.1)	95.0 (94.2–95.7)	95.8 (95.0–96.4)
Sex	p = 0.8789	p = 0.9801	p = 0.8544
M	27.4 (25.0–30.0)	95.0 (93.9–95.9)	95.7 (94.6–96.6)
F	27.1 (24.7–29.7)	95.1 (93.7–96.1)	95.8 (94.6–96.8)
Age group, y	p<0.001	p<0.001	p<0.001
0–4	39.2 (32.3–46.5)	71.2 (64.4–77.2)	76.2 (69.6–81.7)
5–9	32.9 (26.6–39.9)	78.2 (71.5–83.6)	78.7 (72.1–84.1)
10–19	40.0 (35.0–45.2)	95.2 (92.5–97.0)	96.2 (93.7–97.7)
20–29	29.7 (24.8–35.2)	97.9 (95.7–99.0)	98.6 (96.5–99.5)
30–39	30.3 (25.2–36.0)	96.3 (93.4–98.0)	96.9 (94.1–98.4)
40–49	27.2 (22.3–32.7)	96.6 (93.8–98.2)	97.7 (95.3–98.9)
50–59	27.0 (22.2–32.4)	97.5 (95.0–98.8)	97.7 (95.1–98.9)
60–69	21.0 (16.7–26.0)	97.0 (94.4–98.4)	97.4 (94.8–98.7)
≥70	17.3 (13.5–21.7)	96.7 (94.2–98.2)	97.2 (94.8–98.6)
Region of residence	p = 0.1465	p = 0.0141	p = 0.0315
Norte	24.8 (21.6–28.3)	96.4 (94.9–97.5)	96.8 (95.3–97.8)
Centro	28.2 (24.3–32.6)	95.2 (93.0–96.7)	95.9 (93.8–97.3)
Lisboa e Vale do Tejo	29.3 (26.3–32.6)	94.2 (92.5–95.6)	95.3 (93.7–96.5)
Alentejo	25.4 (21.7–29.5)	95.3 (93.1–96.9)	96.0 (93.9–97.3)
Algarve	27.6 (23.2–32.5)	91.0 (87.6–93.5)	91.7 (88.4–94.1)
Madeira	31.0 (26.8–35.5)	94.1 (92.0–95.7)	95.6 (93.7–97.0)
Açores	24.4 (20.6–28.6)	93.7 (91.1–95.6)	95.9 (93.8–97.3)

*ISN4COVID-19 study. Weighted to match the distribution of the resident population of Portugal (Census 2021) by sex, age group, and region. p values indicate design-adjusted χ^2 testing used to compare seroprevalence by sex, age group, and region. N, nucleocapsid protein; S, spike protein.

fourth surveys (Appendix Figure 3) (4), comparable to intensive epidemic activity in Portugal during January–June 2022 (10). The age-related pattern of lower N IgG seroprevalence in older age groups observed in our study is in line with age-specific SARS-CoV-2 notifications to the National Epidemiological Surveillance Information System in early 2022 (10) and

similar to results from Canada (11) and Navarra (9), which reported lower postinfection seroprevalence for the older than younger age groups.

Regarding the pediatric population, our results demonstrate high postinfection seroprevalence among children not eligible for COVID-19 vaccination. Among children 0–4 years of age, seroprevalence was >75%, higher than estimates reported for unvaccinated pediatric populations by European Union countries at the beginning of the Omicron BA.1 wave: 28.8% among children 1–4 years of age in Ireland in January 2022 (12); 45% among preschool children in Italy in February 2022 (13); and >4-fold as high as seroprevalence among children recruited in our previous seroepidemiologic study conducted during September–October 2021 in Portugal (ISN-3COVID-19) (Appendix Figure 3) (4). The percentage of persons seropositive for N IgG in the 0–4 year age group was lower (39.2%) than for those positive for S IgG (71.2%). This finding may be associated with a previously reported shorter half-life of N IgG (14). The results regarding N IgG positivity should be interpreted with caution because they may reflect only the most recent infections.

Antibody levels were lower among those at the extremes of age distribution. This finding may be related to the course of the vaccination campaign and age-related immunosenescence. Since September 2021, the first booster vaccinations were rolled out by age criteria; those in the older age groups were vaccinated earlier and experienced a more

Table 2. Geometric mean of specific antibodies against SARS-CoV-2 spike protein IgG, stratified by patient sex, age group, and region of residence, Portugal, April 27–June 8, 2022*

Characteristic	Geometric mean, AU/mL (95% CI)
Sex	
M	4,344.8 (3,909.5–4,828.6)
F	4,662.3 (4,150.5–5,237.1)
Age group, y	
0–4	180.4 (118.9–273.6)
5–9	426.6 (285.4–637.7)
10–19	4,750.8 (3,795.5–5,946.5)
20–29	6,011.5 (5,050.5–7,155.4)
30–39	5,433.3 (4,342.8–6,797.6)
40–49	6,940.7 (5,645.7–8,532.9)
50–59	7,669.3 (6,297.5–9,340.0)
60–69	5,484.6 (4,420.3–6,805.2)
≥70	4,558.5 (3,708.4–5,603.4)
Region of residence	
Norte	5,020.5 (4,358.0–5,783.6)
Centro	5,020.9 (4,158.3–6,062.4)
Lisboa e Vale do Tejo	3,998.1 (3,451.9–4,630.9)
Alentejo	5,038.9 (4,177.2–6,078.3)
Algarve	2,970.2 (2,294.2–3,845.3)
Madeira	5,070.6 (4,188.3–6,138.8)
Açores	4,339.1 (3,523.1–5,344.1)
Positivity for nucleocapsid IgG	
Positive	9,233.6 (8,099.1–10,527.0)
Negative	3,452.8 (3,146.7–3,788.6)

*ISN4COVID-19 study. Weighted to match the distribution of the resident population of Portugal (Census 2021) by sex, age group, and region.

pronounced wane of antibody levels (15) compared with middle-aged adults who were vaccinated more recently. Although starting May 15, 2022, a second booster was offered for persons ≥ 80 years of age and for institutionalized persons, our results have not yet reflected the effect of that change. The second booster recommendation was issued during collection of ISN4COVID-19 data, and at the end of the study period, only 4.4% of the population had received the second booster (6).

Lower antibody levels in children may be associated with postinfection immunity; antibody levels that were lower after infection than after vaccination have been reported (14,15). Furthermore, at the time of data collection, a booster was not recommended for the pediatric population, which may also explain lower antibody levels.

Among the limitations of our study, the nonrandom sampling and recruitment strategy can result in selection bias because participants seeking clinical care might differ from the general population. Also, the study might not capture reinfections, and because seroreversion occurs without recent vaccination or infection, we were unable to estimate a cumulative number of SARS-CoV-2 infections in Portugal.

In summary, almost all persons in the Portugal population have specific antibodies against SARS-CoV-2. Even among children not eligible for vaccination, $\approx 75\%$ have SARS-CoV-2 antibodies. Among adults, IgG values are higher for those in age groups who received their vaccine booster more recently.

Members of ISN4COVID-19 Group: Paulo Gonçalves, Rita Matos, Inês Costa, Nuno Verdasca, Fátima Martins, Jorge Machado, Raquel Guiomar, Ana Rita Torres, Carlos Matias Dias, Ana Loureiro, Filomena Caldeira, Adriana Coutinho, M. Paula Falcão, Alzira Louro, Igor Filipciuc, Marisa Isabel da Conceição Belchior, Claudia Sofia Barão Ferreira, Ingrid Villanueva, Sara Moura, Marlene Silva, Rita Paulino, Conceição Cardoso, Ana Margarida Casaca, Maria Vitória Antunes de Matos, Lúcia Coimbra, Nazaré Boavida, Paula Cristina Justino Gama, Afonso Tavares Leite Barros dos Santos, Ana Maria Cabrita Frota Fernandes, Bela Jerónima Nogueira, Rui Pedro Vieira Ferreira, Rui Manuel Borges Vassal, Paula Barbeiro, Aurora Direito, Ana Paula Peleta Marques, Margarida Freitas, Gil Sequeira, Sandra Vieira, Gil Ferreira, Teresa Reis, Lucilia Araujo, Teresa Rodrigues, Lurdes Correia, Susana Gomes, Sílvia Campos, Maira João Cardoso, Angélica Ramos, Carlos Caldas, Eliana Costa, Joana Costa, José Alves, Jácome Bruges Armas, Ana Rita Couto, Paula Genuína de la Cerda Sarmento Escobar, Sónia Oliveira Dias Ávila, Luís Silva, Patricia Vargas, Maria Noia, Vanessa Cordeiro, Teresa Damião, Rita Pinto,

Helena Rodrigues, Filomena Reis, André Ferreira Pinto, Fátima Vale, Ricardo Rodrigues, Ricardo Castro, Bernardo Silva, Jesuína Duarte, Isabel Santos, Ana Miranda Rosa, Adilia Vicente, José Alves, Raquel Sebastião, Patrícia Pereira, Gizela Ferreira Alves dos Santos, Ana Catarina Faria Guerreiro, Armindo Miguel Rosado Gonçalves, Maria de Fátima Narciso Rolo Raimundo, Manuel Cirne Carvalho, Mário João Santos, Nuno Aguiar, Rui Campaíña, Ana Margarida Godinho, João Pedro Freitas, Rita Batista Coelho, Maria Conceição Miranda Senra Furtado, Miguel Eduardo Magalhães Gouveia, Laura Brum, Ana Paula Farto, Susana Agostinho, Luísa Ponte, Maria Beatriz Tomaz, Joana Ramos, Alexandra Santos, Isabel Forjaz Sampaio, Ana Abreu, Paulo Aguiar, Rita Ribeiro, Ana Guia Pereira, Sandra Vieira, Jorge Nunes Oliveira, Inês Stilwell, Sandra Nóbrega, Iolanda Rodrigues, Marco Marques, Sofia Jorge, Jorge Queiroz, Mavilde Vargues, Carlos Cardoso, Rui Pinto, Ana Filipa Alves, João Fernandes.

I.K. collaborated in the study design and implementation, performed the statistical analysis, and wrote the first draft of the manuscript. A.M., C.H., C.M., S.S., and J.A.S. collaborated on the study design, samples processing, results interpretation, and critically reviewed the manuscript. C.A. and S.R. collaborated in the study implementation, data collection, results interpretation, and critically reviewed the manuscript. A.P.R. coordinated the study, was responsible for the study design and implementation, interpreted the results, and critically reviewed the manuscript. ISN4COVID-19 group members collaborated in the data collection, samples processing, results interpretation and critically reviewed the manuscript. All authors approved the final version of the manuscript and agree to be accountable for all aspects of this work

About the Author

Mrs. Kislaya is a biostatistician in the Department of Epidemiology at Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal. Her primary research interests include influenza and COVID-19 vaccine effectiveness, health surveys, and population-level impact of public health interventions.

References






- Operational considerations for respiratory virus surveillance in Europe. [cited 2023 Jan 3]. <https://www.ecdc.europa.eu/sites/default/files/documents/Operational-considerations-respiratory-virus-surveillance-euro-2022.pdf>
- Kislaya I, Gonçalves P, Gómez V, Gaio V, Roquette R, Barreto M, et al. SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19). *Infect Dis (Lond)*. 2022;54:418–24.

3. Kislaya I, Gonçalves P, Barreto M, Sousa R, Garcia AC, Matos R, et al.; ISNCOVID-19 Group. Seroprevalence of SARS-CoV-2 infection in Portugal in May-July 2020: results of the first national serological survey (ISNCOVID-19). *Acta Med Port.* 2021;34:87-94. <https://doi.org/10.20344/amp.15122>
4. Kislaya I, Gonçalves P, Ramalhete S, Barreto M, Torres AR, Gaio V, et al. SARS-CoV-2 seroprevalence following a large-scale vaccination campaign in Portugal: results of the National Serological Survey, September–November 2021. *Acta Med Port.* 2023;36:5-14. <https://doi.org/a0.20344/amp.18528>
5. National Institute of Health Doutor Ricardo Jorge. Genetic diversity of the novel coronavirus SARS-CoV-2 (COVID-19) in Portugal. August 23th 2022 report. Lisbon (Portugal): The Institute; 2022.
6. European Centre for Disease Prevention and Control. COVID-19 vaccine tracker [cited 2022 Feb 6]. <https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html>
7. Rao JNK, Scott AJ. On simple adjustments to chi-square tests with sample survey data. *Ann Stat.* 1987;15:385-97. <https://doi.org/10.1214/aos/1176350273>
8. Public Health Scotland. Enhanced surveillance of COVID-19 in Scotland – population-based seroprevalence surveillance [cited 2022 Aug 5]. <https://publichealthscotland.scot/id/83780>
9. Glück V, Grobecker S, Köstler J, Tydykov L, Bertok M, Weidlich T, et al. Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel. *Infection.* 2022;50:439-46. <https://doi.org/10.1007/s15010-021-01703-9>
10. Directorate-General for Health, National Institute of Health Doctor Ricardo Jorge. Monitoring of epidemiological situation on COVID-19. Report n°13 – June 8, 2022 [cited 2022 Aug 10]. https://www.insa.min-saude.pt/wp-content/uploads/2022/06/20220608_Monitorizacao_COVID-19.pdf
11. Skowronski DM, Kaweski SE, Fraser M, Reyes RC, Henry B, Levett N, et al. Serial cross-sectional estimation of vaccine- and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada *CMAJ.* 2022;194 :E1599-609. <https://doi.org/10.1503/cmaj.221335>
12. HSE Health Protection Surveillance Centre, Dublin. Seroprevalence of antibodies to SARS-CoV-2 in children aged 1-12 years and adults aged 18+ years: results from National Serosurveillance Programme Collection Cycle 1 [cited 2022 Aug 10]. https://www.hpsc.ie/a-z/nationalserosurveillance-programme/reports/NSP%20combined%20adult%20paeds%20cycle%201%20report_final.pdf
13. Mari A, Garancini N, Barcellini L, Zuccotti GV, Alberti L, Gaia P, et al. SARS-CoV-2 seroprevalence among school-age children in Milan: how has it changed with the fourth pandemic wave? *Pediatr Infect Dis J.* 2022;41:e344-5. <https://doi.org/10.1097/INF.0000000000003583>
14. Stone M, Grebe E, Sulaeman H, Di Germanio C, Dave H, Kelly K, et al. Evaluation of commercially available high-throughput SARS-CoV-2 serologic assays for serosurveillance and related applications *Emerg Infect Dis.* 2022;28:672-83. <https://doi.org/10.3201/eid2803.211885>
15. Guiomar R, Santos AJ, Melo AM, Costa I, Matos R, Rodrigues AP, et al. Monitoring of SARS-CoV-2 specific antibodies after vaccination. *Vaccines (Basel).* 2022;10:154. PMID: 35214613

Address for correspondence: Irina Kislaya, Instituto Nacional de Saúde Doutor Ricardo Jorge, Av. Padre Cruz, 1649-016 Lisbon, Portugal; email: irina.kislaya@insa.min-saude.pt

EID Podcast Emerging Infectious Diseases Cover Art

Byron Breedlove, managing editor of the journal, elaborates on aesthetic considerations and historical factors, as well as the complexities of obtaining artwork for Emerging Infectious Diseases.



Visit our website to listen:

<https://www2c.cdc.gov/emerging-infectious-diseases/podcasts/player.asp?f=8646224>

**EMERGING
INFECTIOUS DISEASES**

Seroprevalence of Specific SARS-CoV-2 Antibodies during Omicron BA.5 Wave, Portugal, April–June 2022

Appendix

Sample design in ISN4COVID-19

ISN4COVID-19 was developed using a two-stage stratified non-probability quota sampling design.

The survey sample was stratified by age group, and the sample size was determined in order to estimate an expected IgG anti-N seroprevalence of 25% with an absolute precision of 5% and a design effect of 1.5 for each stratum, leading to the minimum required sample size of 3897 participants at a national level.

In the first stage, the survey sample was allocated to seven regions in order to obtain estimates with the same level of precision ($\pm 5\%$) in each one, considering the regional SARS-CoV-2 attack rates reported by the National System of Epidemiological Surveillance (SINAVE).


The seven regions of Portugal are subdivided into 25 subregions NUTS III (Nomenclature of territorial units for statistics). The NUTS classification is a hierarchical system for dividing up the territory for statistical purposes implemented in the European Union. The NUT system was established by Commission Regulation (EC) No 1059/2003. NUT III corresponds to an administrative region with a resident population ranging between 150 000-800 000 inhabitants. To ensure geographical survey coverage, we distributed the sample by subregions NUTS III, with an allocation of sampling units proportional to the population size. Within each NUT III, we randomly selected municipalities, and, within selected municipalities, the data collection points were chosen by convenience. The distribution of data collection points is shown in Figure 2.

At the second stage, in each selected data collection point (laboratory or hospital), individuals were recruited according to a pre-established age-sex quota among


those who had a medical prescription to perform blood tests for reasons unrelated to COVID-19.

Confidence intervals for geometric mean


As the distribution of IgG anti-S was right-skewed, we used a geometric mean as a summary statistic. To compute confidence intervals for the geometric mean first we created an auxiliary log-transformed variable $u = \log(\text{anti_s level})$. The arithmetic mean of the auxiliary variable u and its confidence interval $[L; U]$ were then computed based on an approximation to a Normal distribution. In the second step, we applied inverse transformation and converted $[L; U]$ back to the original scale: $[\exp(L); \exp(U)]$.



Appendix Figure 1. Evolution of the relative frequency of SARS-CoV-2 Omicron BA.5 lineage in Portugal between weeks 17 (25/05/2022-01/05/2022) and 23 (06/06/2022-12/06/2022).



Appendix Figure 2. Cumulative uptake (%) of the primary vaccination, the first booster, and the second booster dose in the total population in Portugal, week 52, 2020 (28/12/2020-03/01/2021) - week 23, 2022 (06/06/2022-12/06/2022). Note: Cumulative vaccine uptake was obtained from the European Centre for Disease Prevention and Control COVID-19 vaccine tracker (<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>). To compute cumulative vaccine uptake a total population was used as the denominator.



Appendix Figure 3. Evolution of SARS-CoV-2 anti-N seroprevalence (A) and total seroprevalence (B) by age group in Portugal in ISN3COVID-19 (survey3, September – November 2021) and ISN4COVID-19 (survey 4, April – June 2022). Note: Seroprevalence rates estimated by ISN3COVID-19 (survey3) are presented in blue and seroprevalence rates estimated by ISN4COVID-19 (survey4) are presented in red color.